BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Brevibloc Double Strength In Plastic Container, and when can generic versions of Brevibloc Double Strength In Plastic Container launch?
Brevibloc Double Strength In Plastic Container is a drug marketed by Baxter Hlthcare and is included in one NDA.
The generic ingredient in BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER is esmolol hydrochloride. There are eight drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the esmolol hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Brevibloc Double Strength In Plastic Container
A generic version of BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER was approved as esmolol hydrochloride by HIKMA on August 10th, 2004.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER?
- What are the global sales for BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER?
- What is Average Wholesale Price for BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER?
Summary for BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 4 |
| Raw Ingredient (Bulk) Api Vendors: | 96 |
| Clinical Trials: | 16 |
| Patent Applications: | 703 |
| DailyMed Link: | BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER at DailyMed |
Recent Clinical Trials for BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Zagazig University | Phase 2 |
| Cristália Produtos Químicos Farmacêuticos Ltda. | Phase 4 |
| University Hospital Bispebjerg and Frederiksberg | Phase 4 |
See all BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER clinical trials
Pharmacology for BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER
| Drug Class | beta-Adrenergic Blocker |
| Mechanism of Action | Adrenergic beta-Antagonists |
US Patents and Regulatory Information for BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baxter Hlthcare | BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER | esmolol hydrochloride | INJECTABLE;INJECTION | 019386-005 | Jan 27, 2003 | AP | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Baxter Hlthcare | BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER | esmolol hydrochloride | INJECTABLE;INJECTION | 019386-005 | Jan 27, 2003 | ⤷ Sign Up | ⤷ Sign Up |
| Baxter Hlthcare | BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER | esmolol hydrochloride | INJECTABLE;INJECTION | 019386-005 | Jan 27, 2003 | ⤷ Sign Up | ⤷ Sign Up |
| Baxter Hlthcare | BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER | esmolol hydrochloride | INJECTABLE;INJECTION | 019386-005 | Jan 27, 2003 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER
See the table below for patents covering BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| China | 1981739 | ⤷ Sign Up | |
| Australia | 2002309475 | ⤷ Sign Up | |
| Philippines | 18384 | METHOD FOR TREATMENT OR PROPHYLAXIS OF GARDIAC DISORDERS | ⤷ Sign Up |
| Australia | 546424 | ⤷ Sign Up | |
| Germany | 3584560 | ⤷ Sign Up | |
| Australia | 7893881 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
